FDA Approves Durvalumab-Chemo Combo for Resectable NSCLC
The approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Tag: chemotherapy
All
Latest
FDA Approves Durvalumab-Chemo Combo for Resectable NSCLC
The approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read More
Merck Stops Late-Stage Trial of Vibostolimab-Pembrolizumab Combo in Small Cell Lung Cancer
The phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read More
Tiny Swimming Robots Deliver Chemo Directly to Lung Tumors
Engineers have developed microscopic robots that swim through the lungs to deliver chemotherapy directly to lung tumors.
Read More
High-dose Radiotherapy Plus Chemotherapy Effective NSCLC Therapy
Using high doses of radiation while integrating stereotactic ablative radiotherapy concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.
Read More
AstraZeneca’s NSCLC Therapy Imfinzi Misses Primary Endpoint in Ph3 Study
AstraZeneca’s Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.
Read More
Immunotherapy Before and After Surgery Boosts Lung Cancer Outcomes
Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.
Read More
Merck’s Keytruda Meets Primary Endpoint in Phase 3 Trial for Lung Cancer
The US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read More
Immunotherapy in Malignant Pleural Mesothelioma
New data confirm combination nivolumab and ipilimumab as the best treatment for unresectable malignant pleural mesothelioma.
Read More
FDA Approves Medication to Prevent Chemo Damage in Lung Cancer
The FDA approved the new medication Cosela for injection to decrease the damage to the immune system and bone marrow from chemotherapy administered for lung cancer.
Read More
COVID-19 Could Delay Cancer Treatments
New research suggests that COVID-19 may delay cancer treatments for some patients, who may have weakened immune systems while undergoing cancer treatment.
Read More
FDA Clears Imfinzi for Small Cell Lung Cancer
The US FDA cleared Imfinzi, for use with chemo, to treat patients with extensive-stage small cell lung cancer.
Read More
Imfinzi Trial Shows Drug Can Boost Survival Rates in Lung Cancer Patients
Data from a late-stage trial on the cancer drug Imfinzi, in combination with chemotherapies, demonstrated improvement in survival of certain lung cancer patients, AstraZeneca Plc announced this week.
Read More
Lung Cancer Immunotherapy Advances
Innovations in treatments have transformed how clinicians view lung cancer, reports MedScape....
Read More
Chemotherapy Helping Kids Live with Pulmonary Vein Stenosis
A clinical trial shows that adding chemotherapy to a treatment regimen including catheterization and surgery can deter abnormal cellular growth in children with pulmonary vein stenosis.
Read More
IMRT Linked to Better Tolerance of Chemotherapy in Lung Cancer Patients
NSCLC patients administered intensity modulated radiation therapy (IMRT) had positive health benefits when compared to patients who received 3-dimensional conformal radiation therapy.
Read More